VCYT Veracyte, Inc.
$38.50
Veracyte, Inc. (VCYT) Insider Activity
What the officers, directors and large holders did with their own shares. Only open-market purchases and sales count toward the totals — grants, option exercises and shares withheld for tax are compensation mechanics, not decisions, and they're listed separately below.
Insider signal
In line
Selling ran in line with VCYT's own trailing one-year pace, with 93% of sale value under a prearranged plan.
Cluster activity
0 buyers in the last 30 days
0 buyers in the last 90 days
5 sellers in the last 90 days
Insiders buying
0
0 transactions
Insiders selling
11
61 transactions
Purchases
$0
0 shares
Sales
$22.2M
505,142 shares
Net activity
-$22.2M
purchases less sales
How much of that selling was preplanned? 93% planned / 7% discretionary
10b5-1 plan sales
$20.6M
58 transactions · 470,222 shares
Discretionary sales
$1.5M
3 transactions · 34,920 shares
Largest single sale: $6.9M.
Where they traded
Buy
Sell
Dot area is proportional to transaction value.
No open-market insider purchase on record.
Recent open-market activity
| Date | Insider | Role | Action | Shares | Price | Value | Held after |
|---|---|---|---|---|---|---|---|
| Holstein Jens | Director | Sell 10b5-1 | 5,000 | $40.95 | $204.7K | 27,471 −15.4% of holding | |
| Febbo Phillip G. 2 fills | Chief Scientific & Med Officer | Sell 10b5-1 | 13,110 | $43.05 | $564.4K | 135,753 −8.8% of holding | |
| Chambers Rebecca 2 fills | Chief Financial Officer | Sell 10b5-1 | 3,652 | $43.10 | $157.4K | 167,200 −2.1% of holding | |
| McGuire Annie 2 fills | EVP, General Counsel | Sell 10b5-1 | 3,254 | $43.09 | $140.2K | 132,260 −2.4% of holding | |
| Bhanji Muna | Director | Sell 10b5-1 | 1,864 | $42.97 | $80.1K | 42,718 −4.2% of holding | |
| EASTHAM KARIN 2 fills | Director | Sell 10b5-1 | 3,729 | $52.89 | $197.2K | 15,626 −19.3% of holding | |
| Stapley Marc | Chief Executive Officer | Sell 10b5-1 | 138,051 | $50.12 | $6.9M | 440,494 −23.9% of holding | |
| Leite John | Global Chief Commercial Off | Sell 10b5-1 | 13,975 | $50.07 | $699.7K | 132,305 −9.6% of holding | |
| Chambers Rebecca 2 fills | Chief Financial Officer | Sell 10b5-1 | 3,561 | $49.73 | $177.1K | 175,241 −2% of holding | |
| McGuire Annie 2 fills | EVP, General Counsel | Sell 10b5-1 | 3,176 | $49.76 | $158.0K | 139,016 −2.2% of holding | |
| Wygant Jonathan | VP, Chief Accounting Officer | Sell | 24,000 | $45.40 | $1.1M | 45,434 −34.6% of holding | |
| EPSTEIN ROBERT S | Director | Sell 10b5-1 | 10,000 | $44.01 | $440.1K | 52,446 −16% of holding | |
| McGuire Annie 2 fills | SVP, General Counsel | Sell 10b5-1 | 10,204 | $39.02 | $398.2K | 148,810 −6.4% of holding | |
| Stapley Marc 2 fills | Chief Executive Officer | Sell 10b5-1 | 45,523 | $35.97 | $1.6M | 383,833 −10.6% of holding | |
| Chambers Rebecca 2 fills | Chief Financial Officer | Sell 10b5-1 | 18,341 | $36.14 | $662.9K | 145,137 −11.2% of holding | |
| McGuire Annie 2 fills | SVP, General Counsel | Sell 10b5-1 | 6,658 | $35.55 | $236.7K | 96,370 −6.5% of holding | |
| Leite John | Chief Commercial Officer-CLIA | Sell 10b5-1 | 5,260 | $35.19 | $185.1K | 107,580 −4.7% of holding | |
| Febbo Phillip G. | Chief Scientific & Med Officer | Sell 10b5-1 | 13,425 | $36.16 | $485.4K | 117,346 −10.3% of holding | |
| McGuire Annie 2 fills | SVP, General Counsel | Sell 10b5-1 | 10,739 | $43.13 | $463.2K | 67,860 −13.7% of holding | |
| EASTHAM KARIN 3 fills | Director | Sell 10b5-1 | 20,000 | $45.45 | $908.9K | 27,162 −42.4% of holding | |
| Chambers Rebecca 2 fills | Chief Financial Officer | Sell 10b5-1 | 13,278 | $46.84 | $622.0K | 114,237 −10.4% of holding | |
| Stapley Marc 2 fills | Chief Executive Officer | Sell 10b5-1 | 7,668 | $47.09 | $361.1K | 321,823 −2.3% of holding | |
| McGuire Annie 2 fills | SVP, General Counsel | Sell 10b5-1 | 1,422 | $47.30 | $67.3K | 79,201 −1.8% of holding | |
| Leite John | Chief Commercial Officer-CLIA | Sell 10b5-1 | 1,278 | $47.51 | $60.7K | 82,113 −1.5% of holding | |
| Leite John | Chief Commercial Officer-CLIA | Sell 10b5-1 | 2,808 | $50.00 | $140.4K | 86,291 −3.2% of holding | |
| JONES EVAN/ FA | Director | Sell 10b5-1 | 1,106 | $50.25 | $55.6K | 29,362 −3.6% of holding | |
| Holstein Jens 3 fills | Director | Sell 10b5-1 | 10,000 | $42.36 | $423.6K | 35,708 −21.9% of holding | |
| Wygant Jonathan | VP, Chief Accounting Officer | Sell | 5,102 | $42.33 | $216.0K | 38,745 −11.6% of holding | |
| Wygant Jonathan | VP, Chief Accounting Officer | Sell | 5,818 | $40.21 | $233.9K | 43,847 −11.7% of holding | |
| JONES EVAN/ FA 6 fills | Director | Sell 10b5-1 | 43,196 | $45.06 | $1.9M | 73,256 −37.1% of holding | |
| EASTHAM KARIN | Director | Sell 10b5-1 | 9,674 | $40.02 | $387.2K | 13,554 −41.6% of holding | |
| Chambers Rebecca | Chief Financial Officer | Sell 10b5-1 | 7,000 | $41.00 | $287.0K | 126,158 −5.3% of holding | |
| McGuire Annie | SVP, General Counsel | Sell 10b5-1 | 6,466 | $40.00 | $258.6K | 82,973 −7.2% of holding | |
| Febbo Phillip G. | Chief Scientific & Med Officer | Sell 10b5-1 | 8,349 | $36.02 | $300.7K | 92,441 −8.3% of holding | |
| EPSTEIN ROBERT S | Director | Sell 10b5-1 | 21,473 | $35.08 | $753.2K | 62,446 −25.6% of holding | |
| Leite John | Chief Commercial Officer-CLIA | Sell 10b5-1 | 2,539 | $35.00 | $88.9K | 89,099 −2.8% of holding | |
| McGuire Annie | SVP, General Counsel | Sell 10b5-1 | 2,160 | $35.00 | $75.6K | 89,439 −2.4% of holding | |
| McGuire Annie | SVP, General Counsel | Sell 10b5-1 | 2,283 | $33.69 | $76.9K | 91,599 −2.4% of holding |
Form 4s are due within two business days of a transaction, so this is close to real time — unlike the quarterly 13F data on the Institutional tab. A single large sale often reflects a prearranged 10b5-1 plan rather than a fresh view, so read a pattern of sales rather than any one of them.